HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN program priorities

This article was originally published in The Rose Sheet

Executive Summary

FDA is requesting comments on FY 2005 program priorities for the Center for Food Safety & Applied Nutrition, agency announces in a June 24 Federal Register 1notice. CFSAN anticipates "there will be considerable continuity between the 2004 and 2005 workplans," the notice states. FY 2004 "A" list priorities include a review of phthalates and completion of a labeling guidance on alpha hydroxy acid-containing products (2"The Rose Sheet" May 10, 2004, p. 5). Workplan also will follow the format of the FY 2004 plan, which was divided into four sections - assessing food safety and security, improving nutrition and dietary supplement safety, assuring food and cosmetic safety and assuring food safety: cross cutting areas. Comments are due Aug. 9, and the program priorities will be released this fall, the notice states. FDA's fiscal year begins Oct. 1...

You may also be interested in...

Phthalate Cosmetics Survey Placed On CFSAN Priority List

Amid growing controversy over the use of phthalates in cosmetics, FDA's Center for Food Safety & Applied Nutrition announced that a review of the chemicals is one of the Office of Cosmetics & Colors "A" list priorities for fiscal 2004 (ending Sept. 30)

AAM Slams Medicare Delays For First Generics

The AAM has cited multiple reasons for the failure of Medicare Part D to get new generics to its patients, forcing up their costs. The association has offered a list of suggestions to “ensure that first generics are covered at launch, with lower cost-sharing.”

FDA Recommends Further Limiting Use Of Laparoscopic Power Morcellation

The US FDA is updating its labeling guidance on laparoscopic power morcellation to reflect new evidence showing the treatment may pose a higher cancer risk in older women, as well as to add discussion of containment systems.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts